Use of Stem Cell-Derived Cardiomyocyte and Nasal Epithelium Models to Establish a Multi-Tissue Model Platform to Validate Repurposed Drugs Against SARS-CoV-2 Infection
Godde, N.; O'Brien, C.; Vincan, E.; Vashi, A.; Olliff, S.; Tran, B.; Waters, S.; Goldie, S.; Jansen van Vuren, P.; Riddell, S.; Bruce, M.; Agarwal, V.; Athan, E.; Blasdell, K. R.; Chahal, S.; Creek, D.; Faheem, F.; Jain, H.; Kirkpatrick, C.; Kumar, A.; MacRaild, C.; Muzaffar-Ur-Rehman, M.; Sankaranarayanan, M.; Shah, R.; Styles, I.; Tachedjian, M.; Trevaskis, N.; Singanallur, N.; McAuley, A.; Vasan, S. S.
Show abstract
The novel coronavirus disease (COVID-19) and any future coronavirus outbreaks will require more affordable, effective and safe treatment options to complement current ones such as Paxlovid. Drug repurposing can be a promising approach if we are able to find a rapid, robust and reliable way to down-select and screen candidates using in silico and in vitro approaches. With repurposed drugs, ex vivo models could offer a rigorous route to human clinical trials with less time invested into nonclinical animal (in vivo) studies. We have previously shown the value of commercially available ex vivo/3D airway and alveolar tissue models, and this paper takes this further by developing and validating human nasal epithelial model and embryonic stem cells derived cardiomyocyte model. Five shortlisted candidates (fluvoxamine, everolimus, pyrimethamine, aprepitant and sirolimus) were successfully compared with three control drugs (remdesivir, molnupiravir, nirmatrelvir) when tested against key variants of the SARS-CoV-2 virus including Delta and Omicron, and we were able to reconfirm our earlier finding that fluvoxamine can induce antiviral efficacy in combination with other drugs. Scalability of this high-throughput screening approach has been demonstrated using a liquid handling robotic platform for future Disease-X outbreaks.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Metal Coordinating Inhibitors of Rift Valley Fever virus Replication 93%
- An Endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells 93%
- Difference in TMPRSS2 usage by Delta and Omicron variants of SARS-CoV-2: Implication for a sudden increase among children 92%
Similar papers in this journal
- Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in Human Lung Tissue Cells 96%
- Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of k18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2 95%
- A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and selects for interferon-susceptible mutant viruses 94%
Similar papers in this journal
- The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19. 94%
- Establishment of a screening platform based on human coronavirus OC43 for the identification of microbial natural products with antiviral activity 93%
- Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV 2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case 93%
Similar papers in this journal
- Donor-derived airway ALI model for high-throughput screening of antiviral combinations with concurrent analysis of antiviral efficacy and epithelial toxicity using ciliR 96%
- High-Throughput Functional Assay in Cystic Fibrosis Patient-Derived Organoids Allows Drug Repurposing 90%
- Expanding Clinical Phage Microbiology:Simulating Phage Inhalation for Respiratory Tract Infections 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.